- TLDR Biotech
- Archive
- Page 10
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | January 29 - 30, 2025
Vertex scores FDA approval for non-opioid pain alternative, Merck & Co. halts Winrevair Ph3 early after stellar results & offers med to all 172 trial participants, Blackstone's raised $1.6B thus far of mammoth of $5B+ life science-focused fund, Rentschler exits the CGT market, a Republican senator expresses concerns over RFK Jr.'s anti-vax rhetoric + 34 more stories
Biotech & Pharma Updates | January 28 - 29, 2025
Trump administration quickly reverses federal grant freeze after nationwide chaos, 8VC (with interests in life science and healthcare) targets a $1B Fund VI, Lonza on the look-out for M&A to expand biologics capacity and diversify offerings, CARGO Therapeutics stock collapses after scuttling Ph2 trial of firi-cel due to safety concerns and limited durability + 36 more stories
Biotech & Pharma Updates | January 27 - 28, 2025
Helicore Biopharma launches with $65M to develop antibody for “higher-quality” weight loss, Novo Nordisk's Ozempic scores FDA approval for adults with kidney disease and type 2 diabetes, Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT) delivers positive Ph2a data in alcohol use disorder patients, Atara Biotherapeutics to lay off 50% of workforce by June following FDA double tap of Ebvallo rejection and clinical asset holds + 33 more stories
Biotech & Pharma Updates | January 26 - 27, 2025
Sarepta's Elevidys gene therapy delivers positive Ph3 results in Duchenne muscular dystrophy, a pulitzer-prize winning cancer physician + a LinkedIn co-founder join forces (with a $24.6M seed raise) to launch an AI-powered drug discovery engine (Manas AI), Allakos' AK006 flops in Ph1 chronic spontanous urticaria trial, CDC abruptly halts all collaboration with the WHO thus scuttling any hopes of a transition period + 22 more stories
Biotech & Pharma Updates | January 23 - 26, 2025
Chaos amongst US public health and research agencies, Novo Nordisk gets a boost on next-gen obesity hopeful's amycretin Ph1b/2a data, Aardvark Therapeutics files IPO to fund development of obesity drug candidates, Merck & Co. and Eisai's Keytruda + Lenvima combo (partially) flops in gastroesophageal cancer treatment Ph3 + 28 more stories
Biotech & Pharma Updates | January 22 - 23, 2025
Retro Biosciences aiming for a $1B fundraise, AstraZeneca invests CAD 820M ($572M) in expanding Toronto operations site + creating 700 jobs, another Chinese drug developer (Ab&B Bio-Tech) files for a Hong Kong IPO, Teva Pharmaceuticals’ Copaxone gets a black-box safety warning due to severe allergic reaction risk + 21 more stories
Biotech & Pharma Updates | January 21 - 22, 2025
US federal science meetings and panels abruptly cancelled, Sanofi's Sarclisa approved in EU in multiple myeloma, Samsung Biologics nabs record profits in 2024, Inhibrx's colorectal cancer hopeful faces safety concerns after patient death in Ph1 trial + 31 more stories
Biotech & Pharma Updates | January 20 - 21, 2025
New US-gov backed $500B AI infrastructure project with potential to “revolutionize healthcare”, J&J's Spravato nasal spray lands FDA approval in treatment-resistant depression, FDA lifts hold on Amylyx Pharmaceuticals' Ph1 trial of antisense oligo AMX0114 in ALS, Arctic Therapeutics €26.5M ($27.5M) Series A funds familial dementia and Alzheimer’s disease aspirations + 20 more stories
Biotech & Pharma Updates | January 19 - 20, 2025
President Trump pulls support for the WHO, GSK's PD-1 inhibitor Jemperli lands EMA approval in endometrial cancer, Prolium Biosciences in-licenses a CD20xCD3 bispecific from InnoCare Pharma and KeyMed Biosciences, Immuneel Therapeutics launches India’s first home-grown CAR-T -cell therapy + 11 more stories
Biotech & Pharma Updates | January 16 - 19, 2025
Sage Therapeutics sues Biogen to block $442M takeover attempt, Novo Nordisk's high-dose Wegovy Ph3 trial delivers greater weight loss versus standard dose, U.S. government hands Moderna $590 million to develop bird flu vaccines + 18 more stories
Biotech & Pharma Updates | January 15 - 16, 2025
Samsung Biologics secures massive $1.4B manufacturing contract with unnamed European pharma company, Chromatin Bioscience and EsoBiotec advance an in vivo CAR-T hopeful into clinical trials, Novartis' Entresto catches a break as appeals court temporarily blocks MSN's Entresto generic, Atara Biotherapeutics' Ebvallo rejected by FDA due to third-party manufacturing facility concerns, Teva Pharmaceuticals sues CMS over drug price negotiation program + 24 more stories
Biotech & Pharma Updates | January 14 - 15, 2025
Colossal Biosciences' $200M Series C furthers de-extinction ambitions, Eli Lilly's Omvoh lands FDA approval for Crohn's disease, Samsung Biologics considers building sixth plant to meet growing biologics demand, Pharma CEOs downplay IRA impacts on revenues as next round of CMS negotiations loom, FDA provides receipts on why they rejected Vanda Pharmaceuticals’ gastroparesis treatment hopeful tradipitant + 30 more stories